Literature DB >> 3633135

Human melanoma proteoglycan: expression in hybrids controlled by intrinsic and extrinsic signals.

W J Rettig, F X Real, B A Spengler, J L Biedler, L J Old.   

Abstract

Human malignant melanoma cells express specific chondroitin sulfate proteoglycans (mel-CSPG) on the surface, both in vivo and in vitro. Melanocytes in normal skin show no detectable mel-CSPG but can be induced to express the antigen when cultured in the presence of cholera toxin and the tumor promoter 12-O-tetradecanoylphorbol-13-acetate. Most other cell types do not express mel-CSPG either in vivo or in vitro. A study was designed to examine regulatory signals controlling mel-CSPG expression. The gene encoding mel-CSPG was mapped to human chromosome 15, and this chromosome was introduced into rodent cells derived from distinct differentiation lineages. Three types of mel-CSPG--expressing hybrids were found: (i) hybrids derived from human melanomas; (ii) hybrids derived from human cells that do not express mel-CSPG; and (iii) hybrids derived from human cells expressing mel-CSPG that are antigen-negative but that are induced to express mel-CSPG when cultured on extracellular matrix instead of plastic surfaces. Thus, mel-CSPG expression can be controlled both through intrinsic signals, provided by the differentiation program of the rodent fusion partner, and through extrinsic signals, provided by specific cell-matrix interactions.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3633135     DOI: 10.1126/science.3633135

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  9 in total

Review 1.  Recent advances in the treatment of malignant melanoma with gene therapy.

Authors:  E M Hersh; A T Stopeck
Journal:  Mol Med       Date:  1997-10       Impact factor: 6.354

2.  Cell surface molecules of human melanoma. Immunohistochemical analysis of the gp57, GD3, and mel-CSPG antigenic systems.

Authors:  P Garin-Chesa; H R Beresford; A Carrato-Mena; H F Oettgen; L J Old; M R Melamed; W J Rettig
Journal:  Am J Pathol       Date:  1989-02       Impact factor: 4.307

3.  Extracellular matrix-modulated expression of human cell surface glycoproteins A42 and J143. Intrinsic and extrinsic signals determine antigenic phenotype.

Authors:  W J Rettig; V V Murty; M J Mattes; R S Chaganti; L J Old
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

4.  CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.

Authors:  Xinhui Wang; Takuya Osada; Yangyang Wang; Ling Yu; Koichi Sakakura; Akihiro Katayama; James B McCarthy; Adam Brufsky; Mamatha Chivukula; Thaer Khoury; David S Hsu; William T Barry; H Kim Lyerly; Timothy M Clay; Soldano Ferrone
Journal:  J Natl Cancer Inst       Date:  2010-09-17       Impact factor: 13.506

5.  Two human melanoma xenografts with different metastatic capacity and glycosaminoglycan pattern.

Authors:  J Timár; I Kovalszky; S Paku; K Lapis; L Kopper
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

6.  Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan.

Authors:  G Pluschke; M Vanek; A Evans; T Dittmar; P Schmid; P Itin; E J Filardo; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

7.  Assignment of the human aggrecan gene AGC1 to 15q25-->q26.2 by in situ hybridization.

Authors:  W Just; C Klett; U Vetter; W Vogel
Journal:  Hum Genet       Date:  1993-11       Impact factor: 4.132

Review 8.  Effects of extracellular matrix on the malignant phenotype.

Authors:  S D Luikart
Journal:  Yale J Biol Med       Date:  1988 Jan-Feb

Review 9.  Theranostic impact of NG2/CSPG4 proteoglycan in cancer.

Authors:  Pier Andrea Nicolosi; Alice Dallatomasina; Roberto Perris
Journal:  Theranostics       Date:  2015-02-15       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.